Stock LVTX LAVA THERAPEUTICS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

LAVA Therapeutics N.V. Stock

Equities

LVTX

NL0015000AG6

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-07-02 pm EDT 		5-day change 1st Jan Change
1.89 USD +1.07% Intraday chart for LAVA Therapeutics N.V. -2.58% +19.62%
May. 21 LAVA Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 20 LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2024 * 3.25M 3.5M Sales 2025 * - Capitalization 46.28M 49.87M
Net income 2024 * -31M -33.4M Net income 2025 * -51M -54.96M EV / Sales 2024 * 14.3 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-1.61 x
P/E ratio 2025 *
-1.08 x
Employees 37
Yield 2024 *
-
Yield 2025 *
-
Free-Float 71.28%
More Fundamentals * Assessed data

Chart LAVA Therapeutics N.V.

Dynamic Chart

Latest news about LAVA Therapeutics N.V.

LAVA Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
LAVA Therapeutics N.V. Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 CI
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Slipping Thursday Afternoon MT
Sector Update: Health Care MT
Lava Therapeutics to Study Gammabody Combined With Merck's Keytruda to Treat Metastatic Prostate Cancer MT
Upbeat US Economic Growth Data Lift Sentiment, Driving Premarket Gains for US Equity Futures MT
Lava Therapeutics Shares Rise as Drug Set for Test With Merck's Keytruda DJ
Top Premarket Gainers MT
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc. to Evaluate LAVA-1207 in Combination with KEYTRUDA CI
LAVA Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
HC Wainwright Adjusts Price Target on Lava Therapeutics to $6 From $9, Maintains Buy Rating MT
LAVA Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news

Analyst Recommendations on LAVA Therapeutics N.V.

HC Wainwright Adjusts Price Target on Lava Therapeutics to $6 From $9, Maintains Buy Rating MT
HC Wainwright Starts Lava Therapeutics at Buy With $9 Price Target MT
SVB Securities Adjusts Price Target on Lava Therapeutics to $28 From $25, Keeps Outperform Rating MT
JMP Securities Starts Lava Therapeutics at Market Outperform With $6 Price Target MT
SVB Securities Adjusts LAVA Therapeutics' Price Target to $25 From $23, Keeps Outperform Rating MT
More recommendations

Press releases LAVA Therapeutics N.V.

LAVA Therapeutics N : Results of Annual General Meeting of Shareholders Form 6 K PU
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference GL
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference AQ
LAVA Announces Annual Meeting of Shareholders GL
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference GL
More press releases

Quotes and Performance

1 day+1.07%
1 week-2.58%
Current month+5.00%
1 month-16.37%
3 months-39.42%
6 months+7.82%
Current year+19.62%
More quotes

Highs and lows

1 week
1.80
Extreme 1.8
2.06
1 month
1.80
Extreme 1.8
2.52
Current year
1.49
Extreme 1.49
6.47
1 year
1.13
Extreme 1.131
6.47
3 years
1.13
Extreme 1.131
11.13
5 years
1.13
Extreme 1.131
17.20
10 years
1.13
Extreme 1.131
17.20
More quotes

Managers and Directors - LAVA Therapeutics N.V.

Managers TitleAgeSince
Stephen Allen Hurly CEO
 Chief Executive Officer 56 19-05-31
Fred M. Powell DFI
 Director of Finance/CFO 63 22-10-31
Jessica Truscello CTO
 Chief Tech/Sci/R&D Officer - 21-11-08
Members of the board TitleAgeSince
Stephen Allen Hurly CEO
 Chief Executive Officer 56 19-05-31
Karen Wilson BRD
 Director/Board Member 61 21-03-31
James Noble BRD
 Director/Board Member 65 22-06-14
More insiders

Quotes

Date Price Change Volume
24-07-02 1.89 +1.07% 53,151
24-07-01 1.87 +3.89% 18,430
24-06-28 1.8 -4.26% 89,709
24-06-27 1.88 +1.62% 102,355
24-06-26 1.85 -4.64% 67,484

Delayed Quote Nasdaq, July 02, 2024 at 04:30 pm EDT

More quotes

Company Profile

LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Sector
Biotechnology & Medical Research
Calendar
2024-08-11 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.76 EUR
Average target price
6.706 EUR
Spread / Average Target
+280.92%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
LAVA THERAPEUTICS N.V. Stock LAVA Therapeutics N.V.
+19.62% 49.69M
MODERNA, INC. Stock Moderna, Inc.
+17.72% 44.87B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-10.33% 37.8B
LONZA GROUP AG Stock Lonza Group AG
+41.22% 37.61B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.36% 31.32B
CELLTRION, INC. Stock Celltrion, Inc.
-8.44% 27.4B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.45% 26.32B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.19% 14.07B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.93% 12.5B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.67% 11.23B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. LVTX Stock